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Abstract 
 
Thalassemia Major is the most common single gene disorder which represents a major 
health burden worldwide. The available treatment modalities in conventional medicine i.e. 
blood transfusion (BT) and iron chelation therapies are associated with complications while 
bone marrow transplantation etc. are out of reach of many. Present study is aimed to highlight 
the effective role of Ayurvedic medicines i.e. Dhatri Avaleha, Triphaladi Avaleha and Musta-
Triphaladi Avaleha in the management of Thalassemia Major. Till date total five clinical 
researches have been carried out on Thalassemia Major at PG level in the department of 
Kaumarbhritya at IPGT&RA, Jamnagar. In which a simple random sampling method was 
followed. Patients were divided into two groups, Group A (Trial group with Ayurvedic drug 
intervention and BT) and Group B (Control Group with BT and iron chelation therapy). 
Assessment was done based on the subjective and objective parameters after completion of 
treatment. The data obtained in clinical studies was analyzed by using suitable statistical tests. 
The trial drugs were found to be effective on subjective, objective criteria, BT interval and 
general health status of Thalassemic patients as well as clinically safe. 
 
Key words: Beejadushtijanya Pandu, Dhatri Avaleha, Triphaladi Avaleha, Musta-Triphaladi 
Avaleha. 
 
Introduction 
 Thalassemias are a group of 
inherited disorders of hemoglobin 
synthesis that results from an alteration in 
the rate of globin chain production.(1) It is 
an inherited autosomal recessive blood 
disease where in genetic defect (deletion) 
results in reduced rate of synthesis or no 
synthesis of one of the globin chains that 
makes up hemoglobin. This causes 
formation of abnormal hemoglobin 
molecules, thus causing anemia the 
characteristic presenting symptom of 
Thalassemia.  
 
Types:  
On the basis of clinical 
manifestations, Thalassemia classified as 
Thalassemia Major, Thalassemia 
Intermedia and Thalassemia Minor. 
1) Thalassemia Major: It is the most 
severe form of congenital hemolytic 
anemia. It is characterized by 
transfusion dependent anemia, 
splenomegaly, bony deformities, 
growth retardation and hemolytic faces. 
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Survival is depends on regular blood 
transfusion.  
2) Thalassemia Intermedia: It is of 
intermediate degree of severity that 
does not require regular blood 
transfusion.  
3) Thalassemia Trait (Minor): It is a 
mild asymptomatic condition in which 
there is moderate suppression of β- 
chain synthesis. Patients need very little 
medical care except for the genetic 
counseling. 
  
Epidemiological features: 
As per WHO estimate, 4.5% of the 
world populations are carriers of 
hemoglobinopathies. Over 180 million 
people in the world, more than 20 million 
in India carry β Thalassemia gene. 
Frequency of Thalassemic gene in Indian 
population varies from 0-17% in different 
ethnic groups with average of over 3%. It 
is prevalent among Gujarati (Lohana, 
Kachchhi, Bhanushali, Mahera), Punjabi, 
Sindhi, Agri (Mumbai), Goud Saraswat 
etc. communities.(2) The figure of 
Thalassemic patients in Gujarat is 3,000. 
The Thalassemia centre at GG Hospital, 
Jamnagar alone has a record of more than 
250 Thalassemia Major children who are 
undergoing the conventional treatment.(3) 
 
Present day medical approach and its 
limitations:  
The various treatment modalities 
available for Thalassemia Major and their 
limitations   are described below:(4) 
 Blood transfusion (BT) therapy: The 
medical management of Thalassemia is 
aimed at maintaining Hb% level 
between 10-12 gm/dL. A post 
transfusion Hb level of 9.5 gm/dL is 
said to be sufficient to maintain active 
life. So for this, BT therapy is the only 
treatment which results in 
hemosiderosis (iron overload) as a 
complication. Other major 
complications are those related to 
transmission of infections i.e. Hepatitis 
B, C and HIV. 
 Splenectomy: It should be considered 
when annual blood requirement exceeds 
1.5 times the basal requirement for a 
patient maintaining pre transfusion Hb 
about 10 gm/dL, massive spleen 
enlargement posing a risk of splenic 
rupture or when splenic enlargement is 
associated with left upper quadrant 
pain. Splenectomy should be delayed 
till the patient is 5 years of age as there 
is a risk of overwhelming sepsis below 
this age. 
 Iron chelation therapy: Iron chelators 
used in modern medicine are costly and 
associated with Adverse Drug 
Reactions (ADR) i.e. ophthalmological, 
auditory, allergic reactions, bone 
abnormalities etc. 
 Bone marrow transplantation: It is 
recommended in patients receiving 
adequate chelation, without evidence of 
liver disease and who have HLA 
matched sibling. The problems often 
confronted are chronic graft versus host 
disease and unavailability of HLA 
matched donor as only 1 in 5 siblings 
are HLA identical. It is out of reach of 
poor due to cost factor and success rate 
(in terms of matching donor) is also 
limited. 
 Stem cell therapy: It is an upcoming 
branch and again cost factor is the 
drawback. Poor outcome after stem cell 
transplantation correlates with the 
presence of hepatomegaly and with 
inadequate chelation prior to transplant.  
 
Ayurveda and Thalassemia Major: 
 Thalassemia is not found described 
as such in Ayurveda, but there are some 
Ayurvedic concepts highlighted below that 
help in understanding the etiopathogenesis 
of the disease. 
 
 Concept of Beejadushtijanya 
Vikara (~ genetic disorders): 
Genetic basis of various diseases were 
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known to ancient Acharyas. They 
described possible cause of 
Beejadushti (~ defected mutation) 
and also indicated the possible 
consequences in the form of 
Tridosha Prakopa (~vitiation of 
body humors), Vikrita Avayava (~ 
defected organ) formation 
corresponding to biochemical 
abnormalities or functional 
abnormalities and structural defects 
related to Upatapti of Beeja or 
Beejabhaaga. They described genetic 
basis for various diseases like Arsha (~ 
piles), Prameha (~ diabetes mellitus), 
Kushtha (~ skin disorders) and so on. 
All are Asadhya (~ incurable) in 
nature.(5) Acharya Charaka described 
Beejadushtijanya Vikaras,(6) wherein 
he explained that specific Avayava (~ 
organ) would be Vikrita (~ defected), if 
Doshas (~ humors) vitiate specific 
Beeja (~ sperm or ovum) or 
Beejabhaaga (~ chromosomes).  
 
Table 1: Showing some classical terms, 
nearer terms in genetics and terms for 
Thalassemia 
Terms in 
classics 
Nearer 
terms in 
genetics 
Terms 
for 
Thalasse
mia 
Beeja Sperm, 
Ovum 
and 
zygote   
Sperm, 
Ovum 
and 
zygote 
Beejabhaaga Chromos
omes 
Chromos
omes 16 
& 11 
Beejabhaagaa
vayava 
Gene 
locus: 
Promoter 
region, 
Exons, 
Introns 
 &  
gene 
cluster 
 
 Concept of Atulya Gotra Vivaha (~ 
non consanguineous marriages): It is 
also mentioned in Ayurvedic classics 
that Tulya Gotra Vivaha 
(consanguineous marriages) should not 
be done.(7) The reason for it is 
presumed that Tulya Gotra Vivaha will 
increase the chances of genetic and 
hereditary disorders. Hence, Ayurveda 
propagates Atulya Gotra Vivaha. 
 
 Concept of Anukta Vyadhi (~ 
unknown disease): The methodology 
of understanding Anukta Vyadhi has 
been described in Charaka Samhita 
based on Aaptopadesha Pramana (~ 
words of the expert).(8) Following that 
Thalassemia may be correlated to 
Beejadushtijanya Panduroga. The 
composite picture about this disease can 
be drawn considering points mentioned 
in classics in the light of knowledge 
available in the modern medical 
discipline. 
 
Table 2: Showing Ayurvedic key points 
and similar terms in modern science for 
Thalassemia Major 
Ayurvedic 
terminology 
Nearer term in 
modern science 
(for Thalassemia 
Major) 
Evam 
Prakopanam 
Aggravating factors 
of the disease 
Evam Yonim Pathogenic material 
of the disease  
Evam 
Utthaanam 
Etiology  of the 
disease  
Evam 
Aatmaanam 
Specific features of 
the disease  
Evam 
Adhisthaanam 
Location of the 
disease  
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Evam 
Vedanam 
Knowledge of the 
disease  
Evam 
Samsthaanam 
Symptom of the 
disease  
Evam 
Upadravam 
Complication of the 
disease  
Evam Vriddhi, 
Sthaana, 
Kshayam 
Accumulation, stasis, 
diminution of 
symptoms 
 Evam 
Udarkam 
Consequences of the 
disease, sequalae of 
the disease 
Evam 
Naamam 
Name of the disease  
Evam Yogam Treatment or 
management 
Evam 
Pratikaara, 
Nivritti, 
Pravritti 
Disappears and 
prevention of the 
disease 
 
Samprapti (~etiopathogenesis) of 
Thalassemia according to Ayurveda: 
In the case of Thalassemia the 
Upatapti of Beejabhaagaavayava is the 
main cause and consequent 
Vishamaavastha of Dosha, Dhatu and 
Mala (~ disequilibrium of humors, body 
constituents and proper excretion of 
waste products) which can lead to 
Lakshanas (~ sign and symptoms) of 
Tridosha Prakopa. Pitta Pradhana 
Tridosha (~ pitta dominant body humors) 
affects the functions of Raktavaha Srotasa 
(~ micro channels of blood n its indices) 
and ultimately the process of formation of 
Rakta Dhatu is affected and produces 
Raktavikriti (~ abnormality of blood 
indices). Persistent production of Vikrita 
Rakta Dhatu leads to various symptoms in 
the form of Tridoshajanya Pandu. As the 
disease Thalassemia is also compatible 
with life it can be considered as Asadhya in 
nature.  
 
Ayurvedic drug intervention in 
Thalassemia:   
As iron overload is the main 
complication of Thalassemia Major which 
results as a consequence of repeated BT, 
excess iron should be removed from the 
body. This can be achieved by prolonging 
BT interval and searching for orally active 
iron chelators which should be palatable, 
inexpensive, non-toxic etc.  
There are so many drugs (herbals 
and also minerals) mentioned in 
Rasashastra suggested for Loha 
Sevanajanya Vikara Prashamana (~ drugs 
for diseases/complications due to intake of 
iron/iron containing drugs and iron 
overload), Lohashodhana Gana,(9)  
Lohamarana Gana(10) and Lohadravaka 
Gana(11) (~ specific set of drugs used for 
purification of Ashuddha Loha- ~  impure 
iron) etc. which can be used as iron 
chelators to decrease the iron 
overload due to similarity of 
symptoms between Ashuddha Loha 
Sevanajanya Vikara (~ diseases produced 
by excessive/impure iron intake) and 
complications of Thalassemia i.e. iron 
overload. 
In spite of these, some drugs 
mentioned in Ayurvedic classics in various 
diseases also can be used in the 
management of Thalassemia according to 
clinical manifestations of the disease. i.e. 
drugs used in Panduroga Chikitsa (~ 
anemia), Yakrita Vikara Chikitsa (~ 
hepatic disorders), Pleehaa Vikara 
Chikitsaa (~ splenic disorders), Rakta 
Shodhana (~purification of blood), 
Srotoshodhana (~ body channels cleanser), 
Lekhana (~ scraping property), Bhedana (~ 
piercing),  Tridoshahara (~ normalize all 
body humors), Rasayana (~ adjuvant), 
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Vayahasthapana (~ anti ageing), Balya (~ 
strengthening) drugs etc. 
 
Details of research works on 
Thalassemia Major: 
 Till date a total of 5 research works 
have been carried out on Thalassemia 
Major in Kaumarbhritya department, 
Institute for Post Graduate Teaching & 
Research in Ayurveda (IPGT&RA), 
Gujarat Ayurved University (GAU), 
Jamnagar. Details are given in table 3. 
 
Table 3: Showing details of clinical 
research works on Thalassemia Major 
conducted at Kaumarbhritya 
department, IPGT&RA, GAU, 
Jamnagar 
Stu
dy 
No. 
Name 
of 
Researc
her 
Ye
ar 
No. of 
Pts. 
registe
red 
Age 
Grou
p 
1. 
Singh R. 
et al 
(12,13) 
200
7 
19 
1-15 
Years 
2. 
Jadhav 
S. et al 
(14,15) 
200
9 
30 
1-15 
Years 
3. 
Patalia 
A. et al 
(16,17) 
201
1 
32 
1-15 
Years 
4. 
Rathod 
R. et al 
(18) 
201
3 
41 
6 
Mont
hs-12 
Years 
5. 
Rajgolk
ar S. et 
al (19) 
201
4 
42 
6 
Mont
hs- 12 
Years 
 
 In addition to these 2 research 
works have been carried out in department 
of RS & BK, IPGT&RA, Jamnagar on 
Gandhakadi Yoga on Thalassemic iron 
overload.(20,21) In which standardization, 
pharmaceutical, pharmacological, 
toxicological studies of Gandhakadi Yoga 
and also clinical observations on healthy 
volunteers were done. Gandhakadi Yoga 
has been evaluated for iron sorbitol 
induced iron overload in albino rats.(22) 
The quality control parameters of 
Gandhakadi Yoga tablets (microscopic and 
physico-chemical) have been 
published.(23,24) 
 
Aims and Objectives 
 To review previous clinical researches 
on Thalassemia Major conducted at 
IPGT & RA, Jamnagar. 
 To highlight the effective role of 
Ayurvedic medicines (i.e. Dhatri 
Avaleha, Triphaladi Avaleha and 
Musta-Triphaladi Avaleha) in the 
management of Thalassemia Major. 
 
Materials and Methods 
Patients:  
Diagnosed patients of Thalassemia 
Major attending the OPD of dept. of 
Kaumarbhritya, IPGT&RA, GAU, 
Jamnagar and additionally patients were 
registered from Thalassemia ward of G.G. 
Hospital, Jamnagar. 
 
Inclusion criteria:  
Diagnosed cases of Thalassemia 
Major. 
 
Exclusion criteria:  
Patients with HIV, HBV infection, 
hepatic failure, DM, TB etc., patient 
having BT interval for less than 12 days, 
patient undergone Splenectomy were 
excluded. 
The selected patients were 
randomly divided into two groups, viz. 
1. Trial group (Group A): In this group 
along with blood transfusion trial drugs 
(i.e. Avaleha) were administered orally 
with Godugdha (cow milk) as Anupana. 
Adult dose of Avaleha was taken 1 
Pala (~ 48 gm)(25) and child dose was 
calculated according to Young’s 
formula. [Table 4] 
2. Control Group (Group B): In all the 
five studies, the standard treatment with 
blood transfusion and iron chelators as 
and when required served as control 
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group; no Ayurvedic intervention was 
done in control group.  
 
Table 4: Showing details of trial groups 
of research works 
Study 
No. 
Name of 
Trial 
drug  
Duration 
of 
treatment 
Follow 
Up 
1. Dhatri 
Avaleha 
2 months 
2 
months 
2. Triphaladi 
Avaleha 
2 months 
2 
months 
3. Triphaladi 
Avaleha 
12 weeks 
8 
weeks 
4. Triphaladi 
Avaleha 
12 weeks 
8 
weeks 
5. Musta-
Triphaladi 
Avaleha 
12 weeks 
8 
weeks 
 
Methods of sampling: Simple random 
sampling method. 
Method of research: Open clinical trial. 
Drugs: All the trial drugs were prepared in 
the pharmacy of Gujarat Ayurved 
University, Jamnagar and 
pharmacognostical and analytical studies 
were done in laboratories of IPGT&RA, 
GAU, Jamnagar. 
 
Criteria of assessment: 
 A special proforma was prepared 
to study the etiopathogenesis and response 
to the given treatment and any 
complications. The efficacy of therapy was 
assessed on the basis of suitable scoring 
pattern. 
 Objective Criteria: Routine 
hematological investigations were 
performed along with biochemical 
investigations for assessment of liver 
function and iron overload. 
 Subjective Criteria: The subjective 
criteria for assessment include the 
Panduta (~ pallor), Daurbalya (~ 
weakness), Balakshaya (~ chronic 
fatigue), Akshikootashotha (~ puffiness 
around the orbit), Jwara (~ fever), 
Aruchi (~ anorexia), Udarashoola (~ 
abdominal pain), Pleehavriddhi (~ 
splenomegaly), Yakritvriddhi (~ 
hepatomegaly), Atisara (~ loose 
motion), Pindikodweshtana (~ leg 
cramps) and Sandhishoola (~ 
arthralgia). 
 Criteria of assessing overall effect of 
therapy: An assessment scale was 
made to assess the rate of improvement. 
At the end of treatment, the results in 
view of percentage of relief were 
classified. 
 
Statistical analysis: 
The data obtained in clinical 
studies was subjected to statistical tests and 
analyzed in to the following parts: 
 Paired ‘t’ test was applied to evaluate 
the effect of therapy in individual group 
for subjective and objective criteria.  
 Unpaired ‘t’ test was applied to the 
statistical data for evaluating the 
differences in the effect of two groups 
in improvement of subjective and 
objective criteria. 
 Overall effect of therapy in each group 
was calculated with reference to 
percentage improvement in all cardinal 
features. 
 
Results 
Singh R. (2007) in her study (n=19) 
reported that Dhatri Avaleha provided 
insignificant results in all laboratory 
parameters. Statistically significant 
(p<0.01) result was found in BT interval in 
Dhatri Avaleha treated group in 
comparison to control group. 
Jadav S. (2009) in his study (n=30) 
reported that Triphaladi Avaleha provided 
insignificant results in all laboratory 
parameters, except in total proteins (p <0 
.01); in the control group all the laboratory 
parameters were unaffected.  
 Pataliya A. (2011) in his study 
(n=32) reported that Triphaladi Avaleha 
provided statistically highly significant 
decrease (p<0.01) in SGOT and significant 
decrease (p<0.05) in SGPT while 
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statistically insignificant (p>0.05) result in 
rest of the parameters. Control drug 
provided statistically insignificant 
(p>0.05) result in all parameters. 
Rathod R. (2013) in her study 
(n=41) reported that Triphaladi Avaleha 
provided better percentage of relief in Hb, 
S. TIBC and S. Ferritin. These comparative 
data were significant statistically. 
Statistically highly significant (p<0.01) 
decrease was found in SGOT, SGPT, S. 
Bilirubin, S. TIBC, S. Ferritin while 
insignificant (p>0.05) result on rest of the 
parameters. The effect of control drug on 
SGOT, SGPT, S. Bilirubin, S.TIBC was 
found statistically highly significant 
(p<0.01) and statistically insignificant 
(p>0.01) result was found in Hb, S. Iron, S. 
Ferritin. 
 Rajgolkar S. (2014) in his study 
(n=42) reported that Musta-Triphaladi 
Avaleha provided statistically significant 
(p<0.05) increase in Hb and S.TIBC while 
insignificant (p>0.05) increase was found 
in SGOT, SGPT, S. Bilirubin and S. Iron. 
While S. Ferritin was decreased which is 
statistically highly significant (p<0.001). 
Control drug provided statistically 
insignificant (p>0.05) increase in Hb, 
SGOT, SGPT, S. Bilirubin, significant 
(p<0.05) increase in S. Ferritin while 
highly significant (p<0.001) increase in S. 
Iron and S. TIBC. BT Interval was 
increased by a mean of 5.14 days in trial 
group while it was decreased by a mean of 
1.45 days in control group. 
  All of the three trial drugs provided 
relief in all cardinal features of the disease. 
Comparative efficacy of trial group with 
control group was assessed on cardinal 
features and laboratory parameters. 
Overall effect of therapy in each study was 
assessed at the end of treatment course. 
Details are given in Table 5. 
 
 
 
Table 5: Showing the overall effect of therapy (%) 
Assessment of 
results 
Study 1 Study 2 Study 3 Study 4 Study 5 
G-
A 
G-
B 
G-A 
G-
B 
G-A G-B 
G-
A 
G-
B 
G-A 
G-
B 
Maximum 
improvement 
(>75%) 
25 00 00 00 38.46 00 5 00 19.05 00 
Moderate 
improvement 
(51-75%) 
62.5 00 7.69 00 38.46 18.18 65 00 61.9 00 
Mild 
improvement 
(26-50%) 
12.5 00 84.61 00 15.38 36.36 25 00 19.05 00 
No 
improvement            
(0-25%) 
00 100 7.69 100 7.7 45.46 5 100 00 100 
Discussion 
Till date a total of five research 
works have been carried out on 
Thalassemia Major in dept. of 
Kaumarbhritya, IPGT & RA, Jamnagar. 
Among these 1 research work is on Dhatri 
Avaleha, 3 on Triphaladi Avaleha and 1 on 
Musta-Triphaladi Avaleha.  
All of the three trial drugs provided 
relief in all cardinal features of the disease. 
Most of the drugs have properties like 
Aamapachana (~ digestives), Deepana (~ 
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stomachic), Rochana (~ stimulate appetite) 
and Srotoshodhana which correct the Agni 
(~ digestive power) and help to improve 
appetite and digestion, as well as remove 
obstruction in the channels, so that the 
transformation of dhatus becomes 
undisturbed and thus, it relieves 
Daurbalya. Anulomana Guna (~ laxatives) 
helps in the correction of digestive process. 
In this way, Aruchi, Udarashoola, 
Pindikodweshtana, and Sandhishoola are 
relieved. Triphala,(26) Katuki,(27) 
Guduchi(28) and Sharapunkha(29) 
alleviate Jwara due to Jwaraghna Guna (~ 
antipyretic property). The drugs like 
Triphala,(30) Katuki,(31) Haridra,(32) 
Guduchi,(33) Shweta Punarnava,(34) and 
Sharapunkha(35) have Pandughna (~ 
hemetamic), Bhedana, Pittasaraka (~ 
excrete excess pitta), Yakrita-
Pleehaavriddhihara (~ hepeto-spleno 
protective), Raktashodhana (~ blood 
purifier) and Shonitasthapana 
(~hemostatic) properties which relieve 
Panduta, Akshikootashotha, 
Yakritavriddhi, and Pleehavriddhi. 
Tridoshahara, Rasayana, 
Vayahasthapana, Balya drugs enhance 
Bala (~ strength) and general health status. 
Thus, improve the quality of life of 
Thalassemic patients. 
While analyzing the effect of trial 
drugs on laboratory parameters Musta-
Triphaladi Avaleha has shown better result 
in Hb, S. Ferritin and S. TIBC. The 
majority of the symptoms of Thalassemia 
are reported to be the result of iron 
overload in various tissues and organs. S. 
Iron and S. Ferritin level are the criteria for 
assessing iron overload in Thalassemic 
patients. The drugs like Triphala, Haridra, 
Shweta Punarnava belongs to 
Lohashodhana Gana,(9) Guduchi, 
Vidanga, and Manjishtha belongs to 
Lohamarana Gana(10) and Kakamachi 
belongs to Lohadravaka Gana(11) and 
They would have potential iron chelating 
activity and would have contributed to the 
reduction in S. Ferritin.  
Some of the drugs like Katuki, 
Triphala, Guduchi, Sharapunkha etc. have 
hepatoprotective, splenoprotective 
properties which may have decreased 
SGOT, SGPT and S. Bilirubin level. 
Both Dhatri Avaleha and Musta-
Triphaladi Avaleha increased BT interval. 
This may be due to Raktashodhana, 
Raktaprasadana and Shonitasthapana 
properties of drugs which decrease the 
rapid destruction of RBCs, thus prolonging 
their life span and increases the BT 
interval. All these factors increase the 
expectancy of good life of Thalassemic 
patients.   
 
Adverse drug reaction (ADR): All the 
trial drugs found clinically safe as no 
adverse drug reactions were reported 
during treatment period. 
 
 
Conclusion 
 There is no exact correlation to 
Thalassemia Major with any type of 
Pandu. But it can be co-related with 
Beejadushtijanya Panduroga and 
etiopathogenesis of the disease can be 
interpreted by the application of 
methodology described by Acharya 
Charaka in Vimanasthana in context 
of Anukta Vyadhi. 
 Thalassemia Major being an incurable 
disease, improvement in the quality of 
life of the patient, minimizing the 
complications of the disease, as well 
as increasing the life span should be 
given due emphasis. Ayurvedic drugs 
improve the quality of life; maintain 
the patient fit for curative therapies 
like bone marrow transplant and stem 
cell therapy. Hence, Ayurvedic 
medicines are effective in 
management of diseases like 
Thalassemia Major as adjuvant drugs 
along with modern medical 
management. 
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